These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 35789244)
1. Membranoproliferative glomerulonephritis: current histopathological classification, clinical profile, and kidney outcomes. Bernardes TP; Mastroianni-Kirsztajn G J Bras Nefrol; 2023; 45(1):45-50. PubMed ID: 35789244 [TBL] [Abstract][Full Text] [Related]
2. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Nakano M; Karasawa K; Moriyama T; Uchida K; Nitta K Clin Exp Nephrol; 2019 Jun; 23(6):852-858. PubMed ID: 30854618 [TBL] [Abstract][Full Text] [Related]
6. Comparison of laboratory findings in patients with glomerulonephritis classified according to histopathologic diagnosis. Kirac Y; Bilen S; Duranay M Minerva Med; 2014 Apr; 105(2):149-56. PubMed ID: 24727879 [TBL] [Abstract][Full Text] [Related]
7. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G; Nephron; 2020; 144(4):195-203. PubMed ID: 32050203 [TBL] [Abstract][Full Text] [Related]
8. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G; Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy. Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K Cells; 2023 Feb; 12(5):. PubMed ID: 36899849 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. Nargund P; Kambham N; Mehta K; Lafayette RA Clin Nephrol; 2015 Dec; 84(6):323-30. PubMed ID: 26445002 [TBL] [Abstract][Full Text] [Related]
11. Long-term clinical and morphological evaluation of primary membranoproliferative glomerulonephritis. Wu MJ; Shu KH; Chan LP; Lu YS; Cheng CH; Sheu SS; Hsu YH; Lian JD Zhonghua Yi Xue Za Zhi (Taipei); 1996 Jan; 57(1):34-41. PubMed ID: 8820034 [TBL] [Abstract][Full Text] [Related]
13. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Noris M; Daina E; Remuzzi G Nephrol Dial Transplant; 2023 Feb; 38(2):283-290. PubMed ID: 34596686 [TBL] [Abstract][Full Text] [Related]
14. Membranoproliferative Glomerulonephritis Pattern of Injury. Yu SM; Deoliveira M; Chung M; Lafayette R Adv Kidney Dis Health; 2024 May; 31(3):216-222. PubMed ID: 39004461 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics and outcomes of adult patients with idiopathic membranoproliferative glomerulonephritis according to an immunofluorescence-based classification. Elahi T; Ahmed S; Ahmed E; Mubarak M J Nephrol; 2024 Nov; 37(8):2255-2265. PubMed ID: 39400860 [TBL] [Abstract][Full Text] [Related]
16. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L Front Immunol; 2019; 10():1489. PubMed ID: 31316523 [No Abstract] [Full Text] [Related]
17. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III. West CD; McAdams AJ Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679 [TBL] [Abstract][Full Text] [Related]